Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F17%3A10365234" target="_blank" >RIV/00216208:11160/17:10365234 - isvavai.cz</a>
Result on the web
<a href="http://onlinelibrary.wiley.com/doi/10.1111/bcp.13250" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/bcp.13250</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bcp.13250" target="_blank" >10.1111/bcp.13250</a>
Alternative languages
Result language
angličtina
Original language name
Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis
Original language description
AIMS Statins are known to influence the status of adipokines, which play a key role in the pathophysiology of cardiometabolic diseases. As the effect of ezetimibe as an add-on to statin therapy on the impact of statins on plasma adipokines levels is currently unclear, the aim of the present study was to investigate this through a meta-analysis of controlled trials. METHODS A systematic review was performed, followed by a bibliographic search in PubMed, Medline, SCOPUS, Web of Science and Google Scholar databases. Quantitative data synthesis was performed using a fixed- or random-effects model (based on the level of interstudy heterogeneity) and the generic inverse variance weighting method. Effect sizes were expressed as standardized mean difference (SMD) and 95% confidence interval (CI). RESULTS Meta-analysis of 23 controlled trials did not suggest any significant effect of adding ezetimibe on top of statin therapy on plasma concentrations of adiponectin (SMD 0.34, 95% CI -0.28, 0.96; P = 0.288), leptin (SMD -0.75, 95% CI: -2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD -1.06, 95% CI: -2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: -0.08, 0.67; P = 0.124). However, significantly greater reductions in plasma concentrations of tumour necrosis factor alpha (TNF-alpha) (SMD -0.48, 95% CI -0.87, -0.08; P=0.018) were achieved with ezetimibe/statin combination therapy. CONCLUSIONS The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-alpha-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-alpha in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-alpha-lowering effect.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Clinical Pharmacology
ISSN
0306-5251
e-ISSN
—
Volume of the periodical
83
Issue of the periodical within the volume
7
Country of publishing house
GB - UNITED KINGDOM
Number of pages
17
Pages from-to
1380-1396
UT code for WoS article
000403207500003
EID of the result in the Scopus database
2-s2.0-85014748139